Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors

Ítems similars

• Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients
  per: Champagnac, Anne, et al.
  Publicat: (2020)
• Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
  per: Brevet, Marie, et al.
  Publicat: (2010)
• The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
  per: Kim, Hyungjin, et al.
  Publicat: (2017)
• Rapid detection of EGFR mutations in decalcified lung cancer bone metastasis
  per: Boureille, Antoine, et al.
  Publicat: (2020)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  per: Chen, Zhi-Yong, et al.
  Publicat: (2012)